In a recent essay, pediatrician-scientist Peter Hotez proposes a focus on local data, improved benefit-risk communications, actively countering health disinformation, and state-level action to address antivaccine sentiment in the U.S.
Anti-vaccine sentiment isn’t going away any time soon. In a new opinion article published January 8 in the open-access journal PLOS Global Public Health , Prof. Peter Hotez from Baylor College of Medicine, outlines key actions to stem the momentum of anti-vaccine advocates in the U.S. over the next five years.
Anti-vaccine activities in the U.S. transformed to become a politically charged movement during the COVID-19 pandemic as calls for health freedom characterized partisan political activism. In his recent opinion piece, Hotez argues that, as COVID-19 hospitalizations and deaths decline, anti-vaccine attitudes have not decreased but merely shifted—toward childhood vaccinations. Vaccine hesitancy among parents for childhood vaccines is likewise politically divided, and the country has seen re-emergence of multiple preventable childhood illnesses, including whooping cough and measles. Recently, even polio has been detected in wastewater sampling.
Hotez warns that without urgent action, these isolated outbreaks of childhood illnesses may become regular breakthrough epidemics. He outlines short-term steps for researchers, policymakers, and communicators, including updating local-level data to identify pockets of vaccine hesitancy and focusing on state-level actions to maintain vaccination coverage. In addition, he calls for broader efforts to accurately communicate the risks of preventable illnesses and combat disinformation in real time. Instead of relying on the efforts of individual scientists to correct false information, Hotez proposes that a government-established credible website to debunk vaccine myths in easy-to-understand language.
The authors add: “Our vaccine ecosystem is fragile and the troubling rise in cases of measles, pertussis, and other illnesses requires enhanced measures to counter antivaccine activism. Critical steps include mapping of hotspot counties with significant vaccine exemptions, improved benefit-risk communication graphics, exposing disinformation, and implementing sound vaccine policies in state legislatures.”
Press Preview: https://plos.io/4gyfYwh
In your coverage please use this URL to provide access to the freely available article in PLOS Global Public Health : https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0004020
Citation: Hotez P (2025) It won’t end with COVID: Countering the next phase of American antivaccine activism 2025–29. PLOS Glob Public Health 5(1): e0004020. https://doi.org/10.1371/journal.pgph.0004020
Author Countries: United States
Funding: The author received no specific funding for this work.
PLOS Global Public Health
Commentary/editorial
People
8-Jan-2025
Competing Interests: Peter Hotez is a co-inventor on non-revenue generating patents for neglected tropical diseases owned by Baylor College of Medicine (BCM). He is also a co-inventor of a COVID-19 recombinant protein vaccine technology owned by BCM that was recently licensed by Baylor Ventures non-exclusively and with no patent restrictions to several companies committed to advance vaccines for low- and middle-income countries. These include Biological E (India), BioFarma (Indonesia), Incepta (Bangladesh) and ImmunityBio (United States with partnerships is the African Continent including Botswana and South Africa). The co-inventors have no involvement in license negotiations conducted by BCM. Similar to other research universities, a long-standing BCM policy provides its faculty and staff, who make discoveries and that result in a commercial license, a share of any royalty income. Any such distribution will be undertaken in accordance with BCM policy.